Higher Hb at baseline was significantly associated with a lower risk of leukocytopenia (HR 0.74, p = 0.002) and thrombocytopenia (HR 0.8, p = 0.033), as well as severe anemia (HR 0.52, p < 0.001) and “any hematologic event” (HR 0.53, p < 0.001). Here, GSTM1 is linked to anemia.